Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Vathsala A et al. | Analysis of the interactions of immunosuppressive drugs with cyclosporine in inhibiting DNA proliferation. | 1990 | Transplantation | pmid:1689520 |
Yamamoto K et al. | Experimental treatment of autoimmune MRL-lpr/lpr mice with immunosuppressive compound FK506. | 1990 | Immunology | pmid:1689694 |
Mazzaferro V et al. | Studies of the hepatotrophic qualities of FK 506 and CyA. | 1990 | Transplant. Proc. | pmid:1689913 |
Kay JE et al. | The mechanism of action of FK 506. | 1990 | Transplant. Proc. | pmid:1689914 |
Suzuki N et al. | Effects of a novel immunosuppressive agent, FK506, on human B cell activation. | 1990 | Clin. Exp. Immunol. | pmid:1690097 |
Dammeijer PF et al. | Combined effect of low-dose FK 506 and cyclosporine A on skin graft survival. | 1990 | Transplant. Proc. | pmid:1697116 |
Imai K et al. | Pancreaticoduodenal allotransplantation with the use of FK 506, cyclosporine, and triple-regimen immunosuppression. | 1990 | Transplant. Proc. | pmid:1697117 |
Lee KK et al. | Comparison of short-term immunosuppressive therapy with cyclosporine and FK 506 in small-bowel transplantation. | 1990 | Transplant. Proc. | pmid:1702239 |
Takai K et al. | Effects of FK506 on rat thymus: time-course analysis by immunoperoxidase technique and flow cytofluorometry. | 1990 | Clin. Exp. Immunol. | pmid:1702372 |
Okubo Y et al. | FK506, a novel immunosuppressive agent, induces antigen-specific immunotolerance in active Heymann's nephritis and in the autologous phase of Masugi nephritis. | 1990 | Clin. Exp. Immunol. | pmid:1702373 |